Key facts
- Avistone Pharmaceuticals Biotechnology’s last known valuation is $628.3M (Mar 2025).
- It has raised $372.0M; the latest was IPO in Sep 2025.
- Notable investors include IDG Capital, Bain Capital, Cathay Capital, CMG SDIC Fund, Vivo Capital — 11 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Avistone Pharmaceuticals Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Avistone Pharmaceuticals Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avistone Pharmaceuticals Biotechnology
Developer of innovative drugs for tumor treatment. The company develops targeted cancer therapies, committing to treat cancer through precision medicine.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Employees
- 356
- Website
- avistonebio.com/
- Ownership
- In IPO Registration
Avistone Pharmaceuticals Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avistone Pharmaceuticals Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avistone Pharmaceuticals Biotechnology in its N-PORT filings yet. We sweep new filings monthly.